India’s Commerce Ministry Moves To Block Generic Approval Proposal
This article was originally published in PharmAsia News
One Indian Cabinet office has intervened to block a proposal by the country's drug authority to withhold market approval for generics of patented drugs. The commerce ministry moved to block the proposal on grounds the patent agency should not be involved in the drug-approval process. The Drug Controller General of India had proposed to involve the patent office in the denial effort. The commerce ministry says approvals should be based on whether a drug should be approved for the market and that the issue of a patent should not be a criterion in that decision. (Click here for more
You may also be interested in...
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.